NET PROFIT (x1000 SEK)
EMPLOYEES
Chosa Oncology AB
Closing information (x1000 SEK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
274
|
544
|
1,476 |
| Earnings before taxes |
-9,594
|
-23,752
|
-41,112 |
| EBITDA |
-9,030
|
-22,742
|
-41,116 |
| Total assets |
16,589
|
19,426
|
27,885 |
| Current assets |
7,033
|
9,525
|
27,885 |
| Current liabilities |
2,772
|
2,015
|
18,841 |
| Equity capital |
13,817
|
17,411
|
9,044 |
| - share capital |
12,770
|
11,677
|
3,428 |
| Employees (average) |
1
|
1
|
4 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
83.3%
|
89.6%
|
32.4% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-56.2%
|
-119.5%
|
-142.1% |
| Current ratio |
253.7%
|
472.7%
|
148.0% |
| Return on equity (ROE) |
-69.4%
|
-136.4%
|
-454.6% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
-3
|
0 |
| Chg. No. of employees % |
0%
|
-75%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.